Navigation Links
Study links molecule to muscle maturation, muscle cancer
Date:12/30/2008

COLUMBUS, Ohio Researchers at The Ohio State University Comprehensive Cancer Center have discovered that a molecule implicated in leukemia and lung cancer is also important in muscle repair and in a muscle cancer that strikes mainly children.

The study shows that immature muscle cells require the molecule, called miR-29, to become mature, and that the molecule is nearly missing in cells from rhabdomyosarcoma, a cancer caused by the proliferation of immature muscle cells.

Cells from human rhabdomyosarcoma tumors showed levels of the molecule that were 10 percent or less of those in normal muscle cells. Artificially raising the level of the molecule in the cancer cells cut their growth by half and caused them to begin maturing, slowing down tumor growth.

MiR-29 is a type of microRNA, a family of molecules that helps regulate the proteins cells produce. Researchers say this study is unusual because it also sheds light on the how a microRNA itself is regulated.

"This study shows that there is a connection between this microRNA, muscle development and rhabdomyosarcoma," says principal investigator Denis C. Guttridge, associate professor of molecular virology, immunology and medical genetics and a researcher with Ohio State's human cancer genetics program.

"The findings should give us a better understanding of muscle repair and development, and of rhabdomyosarcoma, and could lead to new treatments for this and other muscle diseases," he says.

The study is published in a recent issue of the journal Cancer Cell.

Guttridge and his colleagues discovered that the gene for miR-29 is silenced by the action of a protein, called NF-B (pronounced, NF kappa B). Their study shows that this protein is present at high levels in rhabdomyosarcoma cells, and that this keeps miR-29 shut off, preventing muscle progenitor cells from maturing.

When they raised the level of the microRNA molecule in the cells, or lowered the level of the NF-B protein, the cells' growth rate dropped two fold, and they began taking on the appearance of mature muscle cells. The modified cells also formed significantly smaller tumors when transplanted into an animal model than did typical rhabdomyosarcoma cells.

"High levels of the protein silence miR-29, which blocks differentiation, causing muscle cells to remain immature. If we can restore the levels of miR-29 in patients," Guttridge says, "it might provide a new therapy for this childhood cancer and perhaps other muscle diseases."


'/>"/>

Contact: Darrell E. Ward
darrell.ward@osumc.edu
614-293-3737
Ohio State University Medical Center
Source:Eurekalert  

Related biology news :

1. Study shows competition, not climate change, led to Neanderthal extinction
2. Facial expressions of emotion are innate, not learned, says new study
3. Recipe for capturing authentic embryonic stem cells may apply to any mammal, study suggests
4. Study first to pinpoint why analgesic drugs may be less potent in females than in males
5. Study links ecosystem changes in temperate lakes to climate warming
6. New edition of laboratory manual includes cutting-edge techniques to study gene regulation
7. TGen, Scottsdale Healthcare, Mayo Clinic study new drug to stimulate immune system of cancer victims
8. Scientists study how asbestos fibers trigger cancer in human cells
9. Male dinosaurs may have been prehistoric babysitters, study shows
10. Study: Did early climate impact divert a new glacial age?
11. Purdue study suggests warmer temperatures could lead to a boom in corn pests
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Study links molecule to muscle maturation, muscle cancer
(Date:12/16/2016)... --  IdentyTechSolutions America LLC , a leading provider ... a cutting-edge manufacturer of software and hardware security ... integrated solutions that comprise IDT biometric readers and ... IdentyTech,s customers with combined physical identification and anti-tailgating ... theft. "We are proud to use ...
(Date:12/16/2016)... , Dec. 16, 2016 The global wearable medical ... 12.14 billion by 2021 from USD 5.31 billion in 2016, at ... ... mainly driven by technological advancements in medical devices, launch of a ... preference for wireless connectivity among healthcare providers, and increasing focus on ...
(Date:12/15/2016)... 15, 2016   WaferGen Bio-systems, Inc. (NASDAQ: ... company, announced today that on December 13, 2016, it ... The Nasdaq Stock Market LLC which acknowledged that, as ... WaferGen,s common stock had been at $1.00 or greater ... compliance with Listing Rule 5550(a)(2) of the Nasdaq Stock ...
Breaking Biology News(10 mins):
(Date:1/17/2017)... 17, 2017  Protagonist Therapeutics, Inc. (NASDAQ: ... initiated a global Phase 2b induction study in ... targets alpha4beta7 integrin. The aim of this randomized, ... the safety/tolerability and efficacy of PTG-100 in approximately ... severe active disease. "We are ...
(Date:1/16/2017)... ... January 16, 2017 , ... Appellate Court of New Jersey ... appeal filed by India-based Dishman Pharmaceutical & Chemical Ltd. company (DPCL) for its ... of its Dishman Group’s 100% wholly owned New Jersey-based subsidiary Dishman USA located ...
(Date:1/16/2017)... NC (PRWEB) , ... January 16, 2017 , ... ... company, received the prestigious Tibbetts Award from the U.S. Small Business Administration. ... “that have created a significant economic or social impact […] and are considered the ...
(Date:1/14/2017)... San Diego, CA (PRWEB) , ... January 14, ... ... availability of Proximo™, a new service providing complete end-to-end genome assemblies to researchers ... to complete genomes eliminates a major obstacle in answering a wide range of ...
Breaking Biology Technology: